Islanda - islandeză - LYFJASTOFNUN (Icelandic Medicines Agency)

tillotts pharma ab - mesalazinum inn - magasýruþolin tafla - 400 mg

Islanda - islandeză - LYFJASTOFNUN (Icelandic Medicines Agency)

tillotts pharma ab - mesalazinum inn - magasýruþolin tafla - 800 mg

Islanda - islandeză - LYFJASTOFNUN (Icelandic Medicines Agency)

tillotts pharma ab - mesalazinum inn - tafla með breyttan losunarhraða - 1600 mg

Uniunea Europeană - islandeză - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - tocilizúmab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - Ónæmisbælandi lyf - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.

Uniunea Europeană - islandeză - EMA (European Medicines Agency)

novartis europharm limited - brínzólamíð - glaucoma, open-angle; ocular hypertension - augnlækningar - azopt er ætlað að minnka hækkað í auga þrýsting í augu háþrýstingur;opna-horn glaucomaas sér í fullorðinn sjúklingar daufur að beta-blokkum eða í fullorðinn sjúklinga sem beta-blokkum eru handa, eða eins og venjulega meðferð til að beta-blokkum eða prostaglandín hliðstæðum.

Uniunea Europeană - islandeză - EMA (European Medicines Agency)

gedeon richter plc. - follitrópín alfa - anovulation - hormón kynlíf og stillum kynfæri - in adult women:anovulation (including polycystic ovarian disease, pcod) in women who have been unresponsive to treatment with clomiphene citrate;stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (art) such as in vitro fertilisation (ivf), gamete intra-fallopian transfer (gift) and zygote intra-fallopian transfer (zift);follitropin alfa in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. Í klínískum raunir þessar sjúklinga sem voru skilgreind af innræn blóðvatn ace stigi < 1. 2 ae / l. in adult men:follitropin alfa is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism with concomitant human chorionic gonadotrophin (hcg) therapy.

Uniunea Europeană - islandeză - EMA (European Medicines Agency)

merck europe b.v. - follitrópín alfa - anovulation; reproductive techniques, assisted; infertility, female; hypogonadism - hormón kynlíf og stillum kynfæri - egglos (þar á meðal einn eggjastokkum, pcod) í konur sem hafa verið daufur til meðferð við gefa konum með barn á brjósti. Örvun multifollicular þróun í gangast undir myndun fjölda eggja samtímis til að aðstoða æxlun tækni (list) eins og í tilraunaglasi fertilisation (tÆknifrjÓvgun), kynfrumuflutning innan eggjaleiðara flytja (gjÖf) og zygote innan eggjaleiðara flytja (zift). egglos-f í tengslum við gulbúsörvandi hormón (ace) undirbúningur er mælt fyrir örvun tíðahvörf þróun í konur með alvarlega ace og la skort. Í klínískum raunir þessar sjúklinga sem voru skilgreind af innræn blóðvatn ace stigi.

Uniunea Europeană - islandeză - EMA (European Medicines Agency)

zoetis belgium sa - lifandi aróa geni eytt escherichia coli, tegund 078, stofn ec34195 - Ónæmislyf fyrir aves, lifandi bakteríu bóluefni - chicken; turkeys - fyrir virk bólusetningar af neitt grill hænur og framtíð lag / ræktendur í röð til að draga úr jörðu og sár (gollurshússbólga, perihepatitis, airsacculitis) í tengslum við kólígerlar serotype o78.

Uniunea Europeană - islandeză - EMA (European Medicines Agency)

zoetis belgium sa - óvirkja blátunguveiru, sermigerð 1 - Ónæmisfræðilegar upplýsingar - nautgripir - virkt ónæmisaðgerð nautgripa frá 2½ mánaða aldri til að koma í veg fyrir veirublæði af völdum blátunguveiru, sermisgerð 1. upphaf ónæmis: 15 dögum eftir að grunnbólusetningarferlið er lokið. lengd ónæmis: 12 mánuðir.

Uniunea Europeană - islandeză - EMA (European Medicines Agency)

zoetis belgium sa - óvirkja blátunguveiru, sermigerð 8, stofnbtv-8 / bel2006 / 02 - Ónæmisfræðilegar upplýsingar - sauðfé - virk ónæmisaðgerð sauðfjár frá 1. 5 mánaða aldur til að koma í veg fyrir veirublæði af völdum blátunguveiru, sermisgerð 8.